Dataset related to article "Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis"

This record contains raw data related to article "Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis" Abstract Background: The impact of a multidisciplinary management of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis on systemic glucocorticoids or innovative treatments remains unknown. Rule-based natural language processing and text extraction help to manage large datasets of unstructured information and provide insights into the profile of treatment choices. Methods: We obtained structured information from text data of outpatient visits between 2017 and 2022 using regular expressions (RegEx) to define elastic search patterns and to consider only affirmative citation of diseases or prescribed therapy by detecting negations. Care processes were described by binary flags which express the presence of RA, PsA and psoriasis and the prescription of glucocorticoids and biologics or small molecules in each cases. Logistic regression analyses were used to train the classifier to predict outcomes using the number of visits and the other specialist visits as the main variables. Results: We identified 1743 patients with RA, 1359 with PsA and 2,287 with psoriasis, accounting for 5,677, 4,468 and 7,770 outpatient visits, respectively. Among these, 25% of RA, 32% of PsA and 25% of psoriasis cases received biologics or small molecules, while 49% of RA, 28% of PsA, and 40% of psoriasis cases received glucocorticoids. Patients evaluated also by other specialists were treated more frequently with glucocorticoids (70% vs. 49% for RA, 60% vs. 28% for PsA, 51% vs. 40% for psoriasis; p < 0.001) as well as with biologics/small molecules (49% vs. 25% for RA, 64% vs. 32% in PsA; 51% vs. 25% for psoriasis; p < 0.001) compared to cases seen only by the main specialist. Conclusion: Patients with RA, PsA, or psoriasis undergoing multiple evaluations are more likely to receive innovative treatments or glucocorticoids, possibly reflecting more complex cases.本数据集包含与论文《基于规则的自然语言处理关联创新治疗与糖皮质激素使用及多学科评估：针对类风湿关节炎（rheumatoid arthritis, RA）、银屑病关节炎（psoriatic arthritis, PsA）及银屑病（psoriasis）患者的真实世界研究》相关的原始数据。 摘要 背景：类风湿关节炎（RA）、银屑病关节炎（PsA）与银屑病的多学科管理对全身用糖皮质激素或创新治疗方案的影响尚不明确。基于规则的自然语言处理（rule-based natural-language processing）与文本抽取技术可用于处理大规模非结构化信息数据集，并为治疗选择的特征分析提供思路。 方法：本研究采用正则表达式（regular expressions, RegEx）定义弹性搜索模式，通过检测否定表述以仅纳入疾病或处方治疗的明确阳性表述，从2017至2022年的门诊就诊文本数据中提取结构化信息。通过二元标记描述诊疗流程，用以标记各病例中RA、PsA、银屑病的存在情况，以及糖皮质激素、生物制剂（biologics）或小分子药物（small molecules）的处方情况。以就诊次数及其他专科就诊情况为核心变量，采用逻辑回归（logistic regression）分析训练分类器以预测研究结局。 结果：本研究共纳入1743例RA患者、1359例PsA患者及2287例银屑病患者，对应门诊就诊次数分别为5677次、4468次及7770次。其中，25%的RA患者、32%的PsA患者及25%的银屑病患者接受了生物制剂或小分子药物治疗，49%的RA患者、28%的PsA患者及40%的银屑病患者接受了糖皮质激素治疗。与仅由主专科医师接诊的病例相比，同时接受其他专科医师评估的患者更常使用糖皮质激素（RA患者：70% vs 49%；PsA患者：60% vs 28%；银屑病患者：51% vs 40%；p < 0.001），生物制剂/小分子药物的使用比例也更高（RA患者：49% vs 25%；PsA患者：64% vs 32%；银屑病患者：51% vs 25%；p < 0.001）。 结论：接受多专科评估的RA、PsA或银屑病患者更有可能接受创新治疗或糖皮质激素治疗，这可能反映了此类病例的病情更为复杂。